Securian Asset Management Inc. Sells 100 Shares of Insulet Co. (NASDAQ:PODD)

Securian Asset Management Inc. reduced its position in Insulet Co. (NASDAQ:PODD) by 2.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,749 shares of the medical instruments supplier’s stock after selling 100 shares during the quarter. Securian Asset Management Inc.’s holdings in Insulet were worth $979,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Venturi Wealth Management LLC increased its holdings in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares during the period. SBI Securities Co. Ltd. bought a new position in Insulet in the 4th quarter valued at about $36,000. SRS Capital Advisors Inc. increased its holdings in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares during the period. TD Private Client Wealth LLC increased its holdings in Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares during the period. Finally, Friedenthal Financial bought a new position in Insulet in the 4th quarter valued at about $57,000.

Insulet Stock Up 4.4 %

Shares of NASDAQ PODD opened at $255.44 on Friday. The company has a market capitalization of $17.94 billion, a P/E ratio of 44.12, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company’s 50 day moving average price is $272.54 and its 200-day moving average price is $254.96.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Equities analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Transactions at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

PODD has been the topic of several recent analyst reports. StockNews.com lowered shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Canaccord Genuity Group raised their price target on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. raised their price target on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Raymond James restated an “outperform” rating and issued a $328.00 price target (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, TD Cowen raised their price target on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.